<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="545">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582658</url>
  </required_header>
  <id_info>
    <org_study_id>P15-695</org_study_id>
    <nct_id>NCT02582658</nct_id>
  </id_info>
  <brief_title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)</brief_title>
  <acronym>REAL</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Austria (REAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to provide evidence of the effectiveness and obtain patient reported outcome
      (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN +/- Ribavirin (RBV)
      in chronic hepatitis C virus infected participants in Austria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 Weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained virologic response is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usage pattern of treatment regimen in Austria</measure>
    <time_frame>Up to post treatment 12 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the usage pattern of treatment regimen type (± Dasabuvir, ± RBV, intended and actual combination, dose and duration) which is initiated at Day 0 in the Austrian population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of missed Ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with concomitant medications</measure>
    <time_frame>Day 0 to end of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with co-morbidities</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants workability measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C questionnaire</measure>
    <time_frame>Day 0 to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaire measures work time missed, work and non-work activity impairment due to a specified healthy problem during the past seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants quality of life measured with the EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire</measure>
    <time_frame>Day 0 to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Five items in the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) are rated on 5 levels of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of participant activation with the Patient activation Measure (PAM-13) questionnaire.</measure>
    <time_frame>Day 0 to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaire measures patient knowledge, skill and confidence for self-management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient support program (PSP) utilization and satisfaction assessment</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaire to evaluate the frequency of use and satisfaction with the patient support program</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Chronic infection of HCV GT1 or GT4</arm_group_label>
    <description>Participants with confirmed chronic hepatitis C genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic infection of HCV Genotype 1 (GT1) or Genotype 4 (GT4)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced adult male or female patients with confirmed chronic
             hepatitis C, genotype 1 or 4, receiving combination therapy with the interferon-free
             ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the
             current local label

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line
             with the current local label (with special attention to contraception requirements
             and contraindication during pregnancy)

          -  Patients must voluntarily sign and date a patient authorization to use and disclose
             his/her anonymized health data prior to inclusion into the study

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial

        Exclusion Criteria: none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Dworan-Timler, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Vagac</last_name>
    <email>sabine.vagac@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Dworan-Timler, MD</last_name>
    <phone>+43-1-20589-391</phone>
    <email>astrid.dworan-timler@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145947</name>
      <address>
        <city>Gratwein-Strassengel</city>
        <zip>8112</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145947, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145948</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145948, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145939</name>
      <address>
        <city>Hall</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145939, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145938</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145938, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145941</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145941, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145942</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145942, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145949</name>
      <address>
        <city>St. Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145949, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145940</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145940, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145943</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145943, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145944</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145944, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145945</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145945, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145946</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 145946, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 20, 2015</lastchanged_date>
  <firstreceived_date>October 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paritaprevir</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Ombitasvir</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
